Precision Medicine in Solid Tumors
In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy....
Kaydedildi:
| Materyal Türü: | Online |
|---|---|
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
2022
|
| Konular: | |
| Online Erişim: | ONIX_20220916_9783036547916_6 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
| _version_ | 1869526231827873792 |
|---|---|
| collection | Directory of Open Access Books |
| description | In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy. With genomics' increasing ability, a routine transcriptomics analysis of advanced/metastatic cancers is now feasible in most cancer hospitals, including community cancer centers. This is an unprecedented shift in the management of cancers irrespective of their organ types, which not only improved the outcome but also opened several new avenues in research and practice, such as immune-check-point inhibitors, tumor-TME co-evolution in the development of resistance, longitudinal liquid biopsies, biomarkers screening and the management of electronic medical records.This book brings together these crucial areas of investigation. The research presented here attempts to address the current issues to provoke thoughts for the future. The future of precision medicine will have to embrace a shift from in vitro, in vivo/PDX models for the mechanistic study to a more functional test based on the scientific interrogation of genomic data, in the form of functional precision medicine. We will also have to combat the element of noise in the multitudes of data and impart the regulatory structure to make judicious use of the data. The expectations for functional precision medicine are high. We aspire to witness a tremendous improvement in patient outcomes, from better to best, down the road that will match the clinical guidelines. |
| format | Online |
| id | doab-20.500.12854ir-92020 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| record_format | ojs |
| spelling | doab-20.500.12854ir-920202024-03-31T13:10:43Z Precision Medicine in Solid Tumors Dey, Nandini De, Pradip pediatric tumors tumor mutational burden TMB whole-exome sequencing gene panel sequencing immune checkpoint inhibitors glioblastoma prognosis overall survival extent of resection random forest Decision tree personalized precision oncology circulating free DNA liquid biopsy epidermal growth factor receptor tyrosine kinase inhibitor osimertinib comprehensive genomic profiling molecular genotyping intratumor heterogeneity multiple biopsies tumor evolution clonality classification strategic therapeutic intervention thymoma driver mutation sequencing molecular barcoding EGFR mutation EGFR-TKI cfDNA NGS digital enrichment next-generation sequencing solid cancer universal health-care system precision medicine presumed germline findings clinical guideline non-small cell lung cancer outcome adjuvant chemotherapy anaplastic lymphoma receptor tyrosine kinase HNSCC ctDNA tDNA DDR genes PARP inhibitors new drug development next-generation sequencing (NGS) open data regulatory reform tumor profiling test triple-negative breast cancer (TNBC) breast cancer targeted therapy TNBC subtypes immunotherapy cancer screening smoking electronic records PD-L1 cancer-associated fibroblasts resistance chemotherapy CTC immunocytochemistry parallel double-detection laboratory-friendly n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy. With genomics' increasing ability, a routine transcriptomics analysis of advanced/metastatic cancers is now feasible in most cancer hospitals, including community cancer centers. This is an unprecedented shift in the management of cancers irrespective of their organ types, which not only improved the outcome but also opened several new avenues in research and practice, such as immune-check-point inhibitors, tumor-TME co-evolution in the development of resistance, longitudinal liquid biopsies, biomarkers screening and the management of electronic medical records.This book brings together these crucial areas of investigation. The research presented here attempts to address the current issues to provoke thoughts for the future. The future of precision medicine will have to embrace a shift from in vitro, in vivo/PDX models for the mechanistic study to a more functional test based on the scientific interrogation of genomic data, in the form of functional precision medicine. We will also have to combat the element of noise in the multitudes of data and impart the regulatory structure to make judicious use of the data. The expectations for functional precision medicine are high. We aspire to witness a tremendous improvement in patient outcomes, from better to best, down the road that will match the clinical guidelines. 2022-09-16T13:45:32Z 2022-09-16T13:45:32Z 2022 book ONIX_20220916_9783036547916_6 9783036547916 9783036547923 https://directory.doabooks.org/handle/20.500.12854/92020 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/5890 https://mdpi.com/books/pdfview/book/5890 10.3390/books978-3-0365-4792-3 10.3390/books978-3-0365-4792-3 MDPI - Multidisciplinary Digital Publishing Institute 9783036547916 9783036547923 304 Basel open access |
| spellingShingle | pediatric tumors tumor mutational burden TMB whole-exome sequencing gene panel sequencing immune checkpoint inhibitors glioblastoma prognosis overall survival extent of resection random forest Decision tree personalized precision oncology circulating free DNA liquid biopsy epidermal growth factor receptor tyrosine kinase inhibitor osimertinib comprehensive genomic profiling molecular genotyping intratumor heterogeneity multiple biopsies tumor evolution clonality classification strategic therapeutic intervention thymoma driver mutation sequencing molecular barcoding EGFR mutation EGFR-TKI cfDNA NGS digital enrichment next-generation sequencing solid cancer universal health-care system precision medicine presumed germline findings clinical guideline non-small cell lung cancer outcome adjuvant chemotherapy anaplastic lymphoma receptor tyrosine kinase HNSCC ctDNA tDNA DDR genes PARP inhibitors new drug development next-generation sequencing (NGS) open data regulatory reform tumor profiling test triple-negative breast cancer (TNBC) breast cancer targeted therapy TNBC subtypes immunotherapy cancer screening smoking electronic records PD-L1 cancer-associated fibroblasts resistance chemotherapy CTC immunocytochemistry parallel double-detection laboratory-friendly n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Precision Medicine in Solid Tumors |
| title | Precision Medicine in Solid Tumors |
| title_full | Precision Medicine in Solid Tumors |
| title_fullStr | Precision Medicine in Solid Tumors |
| title_full_unstemmed | Precision Medicine in Solid Tumors |
| title_short | Precision Medicine in Solid Tumors |
| title_sort | precision medicine in solid tumors |
| topic | pediatric tumors tumor mutational burden TMB whole-exome sequencing gene panel sequencing immune checkpoint inhibitors glioblastoma prognosis overall survival extent of resection random forest Decision tree personalized precision oncology circulating free DNA liquid biopsy epidermal growth factor receptor tyrosine kinase inhibitor osimertinib comprehensive genomic profiling molecular genotyping intratumor heterogeneity multiple biopsies tumor evolution clonality classification strategic therapeutic intervention thymoma driver mutation sequencing molecular barcoding EGFR mutation EGFR-TKI cfDNA NGS digital enrichment next-generation sequencing solid cancer universal health-care system precision medicine presumed germline findings clinical guideline non-small cell lung cancer outcome adjuvant chemotherapy anaplastic lymphoma receptor tyrosine kinase HNSCC ctDNA tDNA DDR genes PARP inhibitors new drug development next-generation sequencing (NGS) open data regulatory reform tumor profiling test triple-negative breast cancer (TNBC) breast cancer targeted therapy TNBC subtypes immunotherapy cancer screening smoking electronic records PD-L1 cancer-associated fibroblasts resistance chemotherapy CTC immunocytochemistry parallel double-detection laboratory-friendly n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| topic_facet | pediatric tumors tumor mutational burden TMB whole-exome sequencing gene panel sequencing immune checkpoint inhibitors glioblastoma prognosis overall survival extent of resection random forest Decision tree personalized precision oncology circulating free DNA liquid biopsy epidermal growth factor receptor tyrosine kinase inhibitor osimertinib comprehensive genomic profiling molecular genotyping intratumor heterogeneity multiple biopsies tumor evolution clonality classification strategic therapeutic intervention thymoma driver mutation sequencing molecular barcoding EGFR mutation EGFR-TKI cfDNA NGS digital enrichment next-generation sequencing solid cancer universal health-care system precision medicine presumed germline findings clinical guideline non-small cell lung cancer outcome adjuvant chemotherapy anaplastic lymphoma receptor tyrosine kinase HNSCC ctDNA tDNA DDR genes PARP inhibitors new drug development next-generation sequencing (NGS) open data regulatory reform tumor profiling test triple-negative breast cancer (TNBC) breast cancer targeted therapy TNBC subtypes immunotherapy cancer screening smoking electronic records PD-L1 cancer-associated fibroblasts resistance chemotherapy CTC immunocytochemistry parallel double-detection laboratory-friendly n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| url | ONIX_20220916_9783036547916_6 |